相关实验视频
Updated: May 21, 2025

08:49
External Cephalic Version: Is it an Effective and Safe Procedure?
Published on: June 6, 2020
14.4K
普拉诺洛尔对长期分娩中剖腹产率的影响:系统性审查和元分析
Oadi N Shrateh1, Ashna Habib2, Zainab Nazir2
1Faculty of Medicine, Al-Quds University, Jerusalem, Palestine.
Annals of medicine and surgery (2012)
|March 20, 2025
概括
在长时间的分娩期间使用普罗普拉诺可显著降低剖腹产分娩率. 这种β-阻断剂提供了一种安全的选择,可以减少剖腹产,而不会影响其他母亲或新生儿的结果.
科学领域:
- 产科和妇科 产科和妇科
- 药理学 药理学是指药理学的学科.
- 围产儿医学 围产儿医学
背景情况:
- 众所周知,非选择性β-上腺素受体阻塞剂普罗普拉诺洛尔会影响子宫活动.
- 长时间的分娩给母亲和新生儿带来了重大的健康问题.
- 之前的研究表明,普拉诺洛尔有可能增强子宫收缩.
研究的目的:
- 系统地审查和分析普拉诺洛尔在延长分娩的情况下对剖腹产分娩率的影响.
- 评估孕产妇内罗普拉诺洛尔在治疗长期分娩中的安全性和有效性.
主要方法:
- 在多个数据库 (PubMed,Cochrane CENTRAL,Embase等) 中进行系统搜索. 在2023年11月之前.
- 包括随机的临床试验,评估孕产妇和新生儿与产妇内罗的结果.
- 使用固定效应模型计算风险比率,并使用I2统计数据评估异质性.
主要成果:
- 六个随机临床试验被纳入了元分析.
- 与安慰剂相比,在propranolol组观察到剖腹产的显著减少 (RR 0.80,95% CI 0.59-1.09,P=0.02).
- 在二次结果中没有发现显著差异,包括Apgar分数,带动脉pH值,出生体重和新生儿重症监护室入院.
结论:
- 在长时间的分娩期间使用普罗普兰诺与剖腹产分娩率显著降低有关.
- 这些研究结果表明,可安全使用普拉诺洛尔来降低剖腹产产生的发生率.
- 进一步的研究可能会探索最佳剂量和特定患者群体在分娩时使用普拉诺洛.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
398
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
398
Local Anesthetics: Clinical Application as Epidural Anesthesia
403
Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
403
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
520
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
520
Antihypertensive Drugs: Types of β-Blockers
543
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
543
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
695
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
695
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
431
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
431

